Abstract
Background:
The fluctuation or even loss of estrogen level caused by menopause in women, and most gynecological cancers often occur before and after menopause, so the age of menopause may be related to the occurrence of gynecological cancer.
Aim:
To investigate whether the age at menopause is independently associated with the incidence of gynecological cancers and to analyze the possible influencing factors.
Methods:
We selected the NHANES public database to conduct the study, and by excluding relevant influencing factors, we finally included 5706 NHANES participants who had full data on age at menopause and the occurrence of gynecologic cancers to analyze the relationship between the amount of age at menopause and gynecologic cancers based on univariate or multifactorial logistic regression analysis. Further, the relationship between age at menopause and the prevalence of different gynecologic cancers was investigated, and changes in the prevalence of different gynecologic cancers by age at menopause subgroups were observed. Finally, other relevant factors affecting the prevalence of gynecologic cancers were further investigated by subgroup analysis as well as subcluster analysis.
Results:
Univariate logistic regression analysis between age at menopause and gynecologic tumor prevalence revealed a negative association between age at menopause and the prevalence of common gynecologic cancers ovarian and cervical cancer, and after adjusting for the effects of covariates, a higher risk of gynecologic tumors was found with statistically significant differences at earlier age at menopause. The regression results showed a negative association between age at menopause and gynecologic cancer prevalence in cervical and ovarian cancer patients (P<0.01,P<0.01). Cervical cancer (OR: 0.91, 95% CI: 0.87,0.94) and ovarian cancer (OR: 0.90, 95% CI: 0.86, 0.95) were more prevalent among those with younger age at menopause.
Conclusion:
Age at menopause is negatively associated with the prevalence of cervical and ovarian cancers, and the earlier the age at menopause, the greater the risk of developing gynecological cancers.
Introduction
It is estimated that about 1.3 million new gynaecological cancers are diagnosed worldwide each year. Among the global female cancer deaths in 2020, cervical cancer and ovarian cancer ranked 4th and 8th among the three major gynecological malignancies, accounting for 12.4% of female cancer deaths, while endometrial cancer did not enter the top ten (, ). With the great threat of malignant tumors of the female reproductive system (mainly ovarian cancer, endometrial cancer, and cervical cancer) to womenās life safety, the risk factors related to the incidence of these three common gynecological tumors have gradually attracted peopleās attention.
In the clinic, ovarian cancer is a silent killer known for its difficult to find, difficult to treat and easy to recur in female gynecological cancers, although the incidence of ovarian cancer is low, accounting for only 3% of female cancers, but it is one of the highest mortality rates in gynecological cancers (, ). Some scholars believe that multiple ovulation ruptures and repair theoretically increase the chance of malignant mutations, which may be related to factors that affect ovulation such as early menopause, late menarche, and oral contraceptives (). In a randomized controlled trial of dietary modification by the Womenās Health Initiative, postmenopausal women who passed a low-fat diet had a reduced risk of ovarian cancer ().Cervical cancer is a preventable and treatable cancer, more than 70% of which is closely related to HPV human papillomavirus 16, 18 and other serotypes (), HPV vaccination provides a scientific basis for the early prevention and treatment of cervical cancer (). Cervical cancer is also known as the ādisease of wealth disparityā due to significant differences in morbidity and mortality between low- and middle-income countries (LMICs) and relatively high-income countries (HICs), which are determined by resources, including age-appropriate screening, vaccination and necessary treatment. Endometrial cancer mostly occurs after menopause (), which is positively correlated with life expectancy (). Studies have shown that non-antagonistic estrogens, which are not counteracted by progestogens, are associated with an increased risk of cancer, and long-term exposure can lead to endometrial hyperplasia, which greatly increases the chances of atypical hyperplasia developing into type I endometrial cancer. Non-antagonistic estrogens can be caused by pure estrogen therapy, obesity, and anovulatory menstrual cycles, where the ovaries have small estrogen-secreting cells but do not secrete progesterone.
These studies have shown a correlation between the occurrence of these cancers and estrogen levels, and overall, postmenopausal women have lower blood estrogen levels and a relatively low risk of developing these cancers (). Estrogen levels are highest in women during their lifetime, but as women age (usually between 45 and 55 years), the function of the ovaries gradually decreases, eventually stopping ovulation and producing estrogen, called menopause, during which estrogen secretion decreases (, ). As we all know, estrogen is a protective sex hormone, and the fluctuation or even loss of estrogen levels caused by menopause plays an important role in womenās cardiovascular system, osteoporosis and fat metabolism (ā), so the relationship between menopausal age and the incidence of gynecological tumors has also attracted attention. In clinical practice, most cases of gynecologic cancer are diagnosed after menopause (ā), which raises the question: is there an association between age at menopause and the incidence of gynecologic cancer? What is the connection between them, which has attracted the attention of women around the world, and it is becoming increasingly important to achieve universal screening for related cancers in perimenopausal and different menopausal age groups.
The NHANES database has a huge data resource, which includes Demog DataćDietary DataćExamination DataćLaboratory DataćQuestionnaire DataćLimited Access Data. Through this database, we can use it to determine the prevalence of major diseases and risk factors for diseases (ā). Therefore, in this study, we aim to mine data through NHANES database and analyze the relationship between menopausal age and gynecological cancer based on univariate or multivariate logistic regression, whichĀ provides an important scientific basis for womenās health management.
Materials and methods
Study design and sample
We obtained data from the nationally representative National Health and Nutrition Examination Survey (NHANES) (). The survey used a complex multi-stage probability sample representing the civilian population in all 50 states and the District of Columbia in the United States. In the current study, 5706 NHANES participants were ultimately included, representing 21950882 postmenopausal women in the United States, covering 14 years (2007-2020). The survey was approved by the Institutional Review Board of the National Center for Health Statistics and all patientsĀ had informed consent. The flow chart for selecting the study sample is shown in FigureĀ 1. The total population (n=111797) was screened for the non-menopausal population (n=97573). Then among menopausal women, we excluded some groups with incompleteĀ information on menarche and childbirth (n=4492). Of the remaining 9732 participants, groups without complete information on demographics, disease, diet and necessary testing were excluded (n=3730). Finally, to improve the scientific validity and reliability of the results, we excluded from the remaining population those extreme values and premenopausal diagnosis of gynecological population (n=296), resulting in our idealised study data population (n=5706).
FigureĀ 1
Sociodemographic characteristics
Sociodemographic characteristics include age, race, and educational attainment. Race includes non-Hispanic white, non-Hispanic black, Mexican-American, other Hispanic, other race, and education level includes less than high school, high school and high school and beyond.
Nutritional status
To study the nutritional status of the population, we obtained data from the household property to income ratio (PIR) as well as the body mass index (BMI) and energy intake. In general, the higher the PIR, the more it is in terms of nutritional intake and physical work, and its BMI is also relatively higher than that of the low-income group. we divided the data according to the median and selected the household PIR, choosing 2.3% as the cut-off value. The BMI screening was divided into >25Kg/m2 or ā¤25Kg/m2.
Behavioral habits
We categorized behavioral habits by how often they smoked and drank, and participants were divided into: never (less than a hundred cigarettes smoked in a lifetime), before (smoked more). There are more than 100 cigarettes in life, now they donāt smoke at all), and now (more than 100 cigarettes are smoked. cigarettes in life, sometimes or every day). People who drink alcohol are divided into five groups: 1. Never drank less than 1 drink.) 2. Before (Drinking. In the past 12 months, women have drunk more than 1 drink and now do not drink at all), 3 mild (women drink ā„ 1 drink per day, ā„ drink 2 drinks per day. 4. Moderate (2 cups a day for women, 3 cups a day for ā„.), 5. Severe (women ā„ 3 cups a day, ā„ 4 cups a day.) ()ć In addition, the energy intake of the population (kcal) is also a reference variable for behavioral habits. The energy intake is divided into < 1580KJ or ā„1580KJ.
Underlying medical conditions
We included diabetes mellitus and hypertension, two underlying diseases associated with the development and progression of gynecologic cancers. The clinical diagnostic criteria for diabetes mellitus were.1. The doctor informs the diagnosis; 3. Fasting blood glucose ā„ 7.0 mmol/L 2. Glycohemoglobin HbA1c>6.5%;4. Random blood glucoseā„ 11.1 mmol/L; 5. Two-hour OGTT blood glucose ā„ 11.1 mmol/L; 6. Already using diabetes medications or insulin. The clinical diagnostic criteria for hypertension is ā„140/90 mmHg. The average blood pressure standards are as follows:1. If only one blood pressure reading is obtained, the number is judged to be average; 2. If there is more than one blood pressure reading, remove the first reading each time. 3. If the diastolic blood pressure reading is zero, it is not used to calculate the average diastolic blood pressure; 4. If all diastolic blood pressure readings are zero, the average is zero.
Statistical analysis
Data obtained from screening were analyzed using R (v.4.2.1). Statistical analysis of gynecologic cancer incidence by age, age at menopause, race, education, PIR, BMI, smoking, alcohol consumption levels, menarche, childbirth and presence of hypertension and diabetes was performed. Univariate and multivariate logistic regression analysis between different age at menopause and different gynecologic cancers. We included age, race, education level, BMI, PIR, smoking, alcohol consumption, energy intake, menarche, childbirth, hypertension, diabetes, and cancer in different regression models to obtain univariate and multivariate logistic regression statistical results and significance. In the study of the association between age at menopause onset and cervical, we also adjusted for age, race, education, BMI, PIR, smoking, alcohol consumption, energy intake, hypertension, and diabetes, and finally performed subgroup analyses for ovarian and cervical cancers.
Results
The baseline characteristics of the study population are shown in FigureĀ 1, where the overall weighted prevalence of gynecologic cancers was 3.69%. The results showed statistically significant differences in gynecologic cancer prevalence by age, race, education level, PIR, BMI, smoking, alcohol consumption level, energy intake, and presence of hypertension and diabetes mellitus. TableĀ 1. Baseline characteristics of the study population.
TableĀ 1
| Characteristics | Gynecological Cancer | p value | |
|---|---|---|---|
| Total | no | yes | |
| Age~ years | 96.75(91.20,102.29) | 3.25(2.59, 3.92) | |
| 61.68(61.24,62.11) | 58.85(56.56,61.14) | 0.02 | |
| Race~% | <0.01 | ||
| āNon-Hispanic āWhite | 76.95(74.66,79.25) | 83.72(77.39,90.06) | |
| āNon-Hispanic āBlack | 10.01(8.59,11.44) | 4.13(1.91, 6.34) | |
| āMexican American | 4.56(3.54,5.58) | 3.23(1.26,5.19) | |
| āOther Hispanic | 3.92(3.12,4.72) | 4.16(1.28,7.04) | |
| āOther Race | 4.56(3.85,5.26) | 4.76(0.74,8.79) | |
| Education level~% | 0.19 | ||
| āLess than high āschool | 15.64(14.14,17.15) | 15.94(9.99,21.89) | |
| āHigh school | 26.26(24.69,27.84) | 31.33(22.02,40.65) | |
| āMore than high āschool | 58.09(56.02,60.16) | 52.72(42.72,62.73) | |
| Family PIR | 3.11(3.02,3.19) | 2.94(2.64,3.25) | 0.29 |
| BMI~ kg/m2 | 29.73(29.43,30.02) | 31.15(29.67,32.62) | 0.04 |
| Smoking behavior~% | <0.01 | ||
| ānever | 57.57(55.74,59.41) | 43.15(34.10,52.20) | |
| āformer | 27.62(25.84,29.39) | 27.57(18.91,36.23) | |
| ānow | 14.81(13.29,16.33) | 29.28(20.15,38.41) | |
| Alcohol consumption~% | 0.01 | ||
| ānever | 15.70(14.27,17.12) | 8.56(4.26,12.86) | |
| āformer | 18.03(16.69,19.37) | 23.18(15.90,30.46) | |
| āmild | 38.35(36.45,40.25) | 31.20(22.63,39.77) | |
| āmoderate | 19.19(17.63,20.75) | 19.52(9.97,29.07) | |
| āheavy | 8.73(7.65, 9.82) | 17.54(8.14,26.95) | |
| Energy intake~kcal | 1696.78(1673.56,1720.00) | 1717.79(1609.63,1825.95) | 0.70 |
| Hypertension~% | 1.00 | ||
| āyes | 58.07(56.50,59.64) | 61.69(51.40,71.98) | |
| āno | 41.93(40.36,43.50) | 38.31(28.02,48.60) | |
| Diabetes~% | 0.93 | ||
| āyes | 20.73(19.27,22.19) | 18.95(12.43,25.47) | |
| āno | 79.27(77.81,80.73) | 81.05(74.53,87.57) | |
| Menopause~years | 45.21(44.94,45.49) | 40.00(37.84,42.16) | <0.01 |
| First menstruation~years | 12.72(12.66,12.78) | 12.41(12.07,12.75) | 0.10 |
| Livng birth | 2.67(2.60,2.74) | 2.60(2.34,2.86) | 0.62 |
Participant characteristics (N = 5,706) in NHANES 2007ā2020.
OR, odds ratio; CI, confidence interval; PIR, property income ratio; BMI, body mass index; Data are shown as mean (x Ģ )or n (%) and presented incorporating sample weights or prevalence (%) and 95%CI.
Relationship between age of menopause and the prevalence of different gynaecological cancers
The results of univariate and multivariate logistic regression analysis between the onset of menopausal age and gynecologic cancers are shown in TableĀ 2. Among them, There was an inverse association between age at menopause and the prevalence of gynaecological cancer (OR: 0.93, 95% CI: 0.90,0.96), and the difference was statistically significant (P<0.01). Model 1 was adjusted for age and race, and the results showed that there was an inverse association between menopausal age and the prevalence of gynaecological cancer (OR: 0.93, 95% CI: 0.90-0.96), and the difference was statistically significant (P<0.01). Model 2, adjusted for age, race, first menstruation age and living birth, showed an inverse association between age at menopause and gynecologic cancer (OR: 0.93, 95% CI: 0.90-0.96), with statistically significant differences (P <0.01).Model 3 was adjusted for age, race, first menstruation age, living birth, education, BMI, PIR, smoking, alcohol consumption level, energy intake, and showed that there was an inverse association between age at menopause and the prevalence of gynecologic cancer (OR: 0.93, 95% CI: 0.90-0.96), and the difference was statistically significant (P <0.01). Model 4 was adjusted for a age, race, first menstruation age, living birth, education, BMI, PIR, smoking, alcohol consumption level, energy intake, hypertension and diabetes, and showed that there was an inverse association between age at menopause and the prevalence of gynecologic cancer (OR: 0.93, 95% CI: 0.90-0.96), and the difference was statistically significant (P <0.01).The global mean age of women at overall natural menopause was 48.8 years (95% CI 48.3,49.2) and the average age of menopause for women in the United States was 51 years (). Therefore, we divided into 7 groups according to different menopausal ages, as shown in FigureĀ 2, respectively, observing the relationship between menopausal age less than 30 years, between 30 and 35 years old, 36 to 40 years old, 41 to 45 years old, 46 to 50 years old, 51 to 55 years old, and greater than or equal to 56 years old and the occurrence of gynecological cancer, the results showed that the incidence of menopausal women before the age of 35 was greatly increased, and the difference was statistically significant.
TableĀ 2
| outcomes | model | OR(95%CI) | P value |
|---|---|---|---|
| Gynecological Cancer | Crude | 0.93(0.90,0.96) | <0.01 |
| Model1 | 0.93(0.90,0.96) | <0.01 | |
| Model2 | 0.93(0.90,0.96) | <0.01 | |
| Model3 | 0.93(0.90,0.96) | <0.01 | |
| Model4 | 0.93(0.90,0.96) | <0.01 |
Odds ratios (OR), 95% CI, and P values for univariate and multivariate logistic regression analysis between gynecologic cancer and menopause.
Crude is an unadjusted model, model 1 is a model adjusted for age and race, model 2 is a model adjusted for age, race, first menstruation age and living birth. model 3 is a model adjusted for age, race, first menstruation age, living birth, education, BMI, PIR, smoking, alcohol consumption level, energy intake. model 4 is a model adjusted for age, race, first menstruation age, living birth, education, BMI, PIR, smoking, alcohol consumption level, energy intake, hypertension and diabetes.
FigureĀ 2
Relationship between menopause and incidence of gynaecological cancer
To investigate whether menopause is associated with gynecologic age, we performed a regression analysis between menopause and the incidence of three major gynecologic cancers, as shown in FigureĀ 3 for the relationship between age at menopause and the incidence of different gynecologic cancers. After adjusting for age, race, first menstruation age, living birth, education, BMI, PIR, smoking, alcohol consumption level, energy intake, hypertension and diabetes, the regression results revealed that age at menopause was inversely associated with the prevalence of gynecologic cancers in patients with cervical and ovarian cancer (P<0. 01, P<0.01). People of younger menopausal age are more likely to develop cervical cancer (OR: 0.91, 95% CI: 0.87,0.94) and ovarian cancer (OR: 0.90, 95% CI: 0.86,0.95).
FigureĀ 3
Subgroup analysis
The results of the subgroup analysis of gynecologic cancers are shown in TableĀ 3, The results showed that people aged 65(P<0.01) and above with high school education or below(P<0.01), non-Hispanic whites(P<0.01), non-Hispanic blacks(P=0.04), and other Hispanics(P<0.01), had drunk alcohol and still drank alcohol(P=0.01, P=0.02, P=0.01, P=0.01). The prevalence of gynaecological cancer was higher in the population and the prevalence of gynaecological cancer is higher in people with younger menopause age than in people with older menopause.
TableĀ 3
| Subgroup Variable | Gynecological Cancer OR(95%CI) | P value |
|---|---|---|
| Age | ||
| ā<65 | 0.92(0.88,0.95) | <0.01 |
| āā„65 | 0.96(0.90,1.02) | 0.17 |
| Race | ||
| āNon-Hispanic āWhite | 0.93(0.89,0.96) | <0.01 |
| āNon-Hispanic āBlack | 0.93(0.97,1.00) | 0.04 |
| āMexican āAmerican | 0.95(0.87,1.04) | 0.28 |
| āOther āHispanic | 0.89(0.82,0.96) | <0.01 |
| āOther Race | 1.00(0.90,1.12) | 0.96 |
| Education level | ||
| āLess than high āschool | 0.90(0.85,0.95) | <0.01 |
| āHigh school | 0.95(0.89,1.01) | 0.10 |
| āMore than high school | 0.92(0.89,0.96) | <0.01 |
| Family PIR | ||
| ā<2.3 | 0.93(0.90,0.97) | <0.01 |
| āā„ 2.3 | 0.93(0.89,0.98) | <0.01 |
| BMI | ||
| ā<25 | 0.90(0.86,0.95) | <0.01 |
| āā„25 | 0.94(0.90,0.97) | <0.01 |
| Smoking behavior | ||
| ānever | 0.93(0.89,0.97) | <0.01 |
| āformer | 0.92(0.87,0.98) | 0.01 |
| ānow | 0.94(0.88,1.00) | 0.05 |
| Alcohol consumption | ||
| ānever | 0.97(0.90,1.05) | 0.47 |
| āformer | 0.93(0.88,0.98) | 0.01 |
| āmild | 0.94(0.89,0.99) | 0.02 |
| āmoderate | 0.90(0.84,0.97) | 0.01 |
| āheavy | 0.91(0.85,0.98) | 0.01 |
| Energy intake | ||
| ā<1580 | 0.91(0.86,0.96) | <0.01 |
| āā„1580 | 0.94(0.91,0.98) | <0.01 |
| Hypertension | ||
| āyes | 0.93(0.90,0.97) | <0.01 |
| āno | 0.92(0.88,0.97) | <0.01 |
| Diabetes | ||
| āyes | 0.94(0.89,1.00) | 0.04 |
| āno | 0.93(0.89,0.96) | <0.01 |
Odds ratios (OR), 95% CI, and P values for univariate and multivariate logistic regression analysis between gynaecological cancer and menopausal age.
PIR, energy intake is divided into groups according to median;model is adjusted for age, race, first menstruation age, living birth, education, BMI, PIR, smoking, alcohol consumption level, energy intake, hypertension and diabetes.
The results of the subgroup analysis of cervical cancer are described in TableĀ 4, in non-Hispanic whites(P<0.01), non-Hispanic blacks (P=0.01), with high school education or above(P<0.01), who are still drinking alcohol, (P=0.01, P<0.01, P<0.01), age at menopause was inversely correlated with cervical cancer prevalence. The results of the subgroup analysis of ovarian cancer are shown in TableĀ 5, in people under 65 years of age(P<0.01), non-Hispanic whites(P<0.01), Mexican(P<0.01), other Hispanic(P<0.01), other people(P<0.01), never smoked(P<0.01), former smoking(P=0.03), had ever drunk, had consumed alcohol mild and light(P<0.01, P<0.01, P=0.03), had diabetes(P<0.01), the age of menopause was inversely correlated with the prevalence of ovarian cancer.
TableĀ 4
| Subgroup Variable | cancer=Cervical OR(95%CI) | P value |
|---|---|---|
| Age | ||
| ā<65 | 0.90(0.86,0.94) | <0.01 |
| āā„65 | 0.91(0.85,0.98) | 0.01 |
| Race | ||
| āNon-Hispanic āWhite | 0.89(0.85,0.93) | <0.01 |
| āNon-Hispanic āBlack | 0.88(0.80,0.97) | 0.01 |
| āMexican American | 0.91(0.81,1.02) | 0.11 |
| āOther Race | 1.09(0.88,1.34) | 0.43 |
| Education level | ||
| āLess than high āschool | 0.91(0.85,0.97) | <0.01 |
| āHigh school | 0.95(0.891.02) | 0.19 |
| āMore than high āschool | 0.88(0.83,0.92) | <0.01 |
| Family PIR | ||
| ā<2.3 | 0.94(0.90,0.98) | 0.01 |
| āā„ 2.3 | 0.89(0.84,0.94) | <0.01 |
| BMI | ||
| ā<25 | 0.90(0.83,0.96) | <0.01 |
| āā„25 | 0.90(0.86,0.94) | <0.01 |
| Smoking behavior | ||
| ānever | 0.90(0.84,0.96) | <0.01 |
| āformer | 0.88(0.80,0.95) | <0.01 |
| ānow | 0.92(0.86,0.98) | 0.01 |
| Alcohol consumption | ||
| ānever | 0.96(0.86,1.08) | 0.51 |
| āformer | 0.95(0.88,1.03) | 0.19 |
| āmild | 0.93(0.82,0.98) | 0.01 |
| āmoderate | 0.86(0.79,0.94) | <0.01 |
| āheavy | 0.86(0.81,0.92) | <0.01 |
| Energy intake | ||
| ā<1580 | 0.90(0.85,0.97) | <0.01 |
| āā„1580 | 0.90(0.85,0.95) | <0.01 |
| Hypertension | ||
| āyes | 0.82(0.87,0.97) | <0.01 |
| āno | 0.89(0.84,0.94) | <0.01 |
| Diabetes | ||
| āyes | 0.93(0.88,0.98) | 0.01 |
| āno | 0.90(0.86,0.94) | <0.01 |
Odds ratio (OR), 95% CI, and P values for cervical cancer incidence versus univariate and multivariate logistic regression analyses with other covariates.
PIR, energy intake is divided into groups according to median;model is a model adjusted for age, race, first menstruation age, living birth, education, BMI, PIR, smoking, alcohol consumption level, energy intake, hypertension and diabetes.
TableĀ 5
| Subgroup Variable | cancer=Ovarian(95%CI) | P value |
|---|---|---|
| Age | ||
| ā<65 | 0.89(0.84,0.94) | <0.01 |
| āā„65 | 0.95(0.87,1.03) | 0.24 |
| Race | ||
| āNon-Hispanic White | 0.91(0.86,0.96) | <0.01 |
| āNon-Hispanic Black | 0.93(0.82,1.05) | 0.23 |
| āMexican American | 1.25(1.11,1.40) | <0.01 |
| āOther Hispanic | 0.85(0.79,0.92) | <0.01 |
| āOther Race | 0.91(0.86,0.96) | <0.01 |
| Education level | ||
| āLess than high school | 0.88(0.81,0.94) | <0.01 |
| āHigh school | 0.91(0.86,0.96) | <0.01 |
| āMore than high school | 0.92(0.86,0.98) | 0.01 |
| Family PIR | ||
| ā<2.3 | 0.87(0.79,0.96) | 0.01 |
| āā„ 2.3 | 0.91(0.87,0.95) | <0.01 |
| BMI | ||
| ā<25 | 0.89(0.84,0.93) | <0.01 |
| āā„25 | 0.90(0.86,0.95) | <0.01 |
| Smoking behavior | ||
| ānever | 0.91(0.87,0.96) | <0.01 |
| āformer | 0.79(0.64,0.98) | 0.03 |
| ānow | 0.90(0.62,1.16) | 0.40 |
| Alcohol consumption | ||
| ānever | 1.01(0.87,1.17) | 0.91 |
| āformer | 0.91(0.86,0.96) | <0.01 |
| āmild | 0.86(0.78,0.95) | <0.01 |
| āmoderate | 0.90(0.82,0.99) | 0.03 |
| āheavy | 0.89(0.68,1.18) | 0.43 |
| Energy intake | ||
| ā<1580 | 0.87(0.82,0.92) | <0.01 |
| āā„1580 | 0.93(0.87,0.99) | 0.03 |
| Hypertension | ||
| āyes | 0.92(0.88,0.96) | <0.01 |
| āno | 0.83(0.75,0.93) | <0.01 |
| Diabetes | ||
| āyes | 0.89(0.78,1.01) | 0.06 |
| āno | 0.90(0.87,0.94) | <0.01 |
Odds ratio (OR), 95% CI, and P values for ovarian cancer incidence versus univariate and multivariate logistic regression analyses with other covariates.
PIR, energy intake is divided into groups according to median;model is a model adjusted for age, race, first menstruation age, living birth.
Discussion
Changes before and after menopause and their relationship with gynecologic oncology are receiving increasing attention, which is also an important public health issue that has attracted the attention of researchers. Of the hormone levels caused by menopause, estrogen is undoubtedly the most affected (, ). Estrogen is a major female sex hormone that determines secondary sexual characteristics and influences the development and function of the female reproductive system. Changes in this hormone are associated with pathological menopausal syndromes such as sleep/mood disorders, vasodilatory symptoms (including hot flashes and night sweats), urogenital atrophy, bone loss and osteoporosis, psychiatric disorders, skin lesions, cardiovascular disease, metabolic disorders and obesity (, ). While endogenous estrogen protects a womanās body before menopause, continued exposure to exogenous estrogen is a recognized risk factor for many types of cancer. Premature menopause is the premature cessation of estrogen production and ovulation by the ovaries, causing a woman to permanently stop menopause before age 40. Most premature menopause is caused by ovariectomy, or premature ovarian failure due to cancer treatments such as chemotherapy and radiation therapy, and is called āinduced premature menopauseā due to medical treatments such as surgery, chemotherapy, and radiation therapy before age 40. However, a small number of women with premature menopause who have not undergone ovarian surgery stop having cramps at a young age due to physical illness, genetics, emotional stress, or other unknown reasons, a condition known as āPrimary Ovarian Insufficiency (POI)ā (ā). Studies have shown that hormonal and metabolic changes resulting from menopause are associated with cancer risk (). According to a statistical analysis in the United States, the risk of invasive cancer increases exponentially after menopause. This is similar to our experimental findings that the younger the age of menopause, the higher the risk of gynecologic cancers in women. Cancer is now recognized as a metabolic disorder.The development of cancer may be related to premature hormonal changes in a womanās body, which lead to disruption of the bodyās metabolism (, ). This may be an important reason why menopause leads to the development of cancer. Previous studies have implicated estrogen in the development and progression of various cancers, including ovarian and endometrial cancers (ā). In our study, we looked at whether age at menopause was associated with the incidence of gynaecological cancers, using age of menopause as a variable. The results confirmed that there was an inverse relationship between the age of menopause and the incidence of cervical and ovarian cancer, which provided an important scientific basis for universal screening of related cancers in the perimenopausal period and different menopausal age groups. Premature menopause has earlier and longer lasting hormonal changes in the body, which may be a trigger for cancer.
Estrogen is known to be associated with ovarian cancer (). At the cellular level, estrogen binds to ERα leading to transcriptional activation of estrogen-responsive genes, which act on the signaling system for cell division and differentiation, among these genes are proto-oncogenes (such as c-fos, c-myc, and HER2/neu), cell cycle regulation cyclins, growth factors, etc. Membrane-bound G-protein-coupled estrogen receptor (GPER) binds to activate the second messenger system and promote tumor growth. In addition, the metabolic activation of estrogen produces free radicals that cause mutations, and the accumulation of various genetic mutations in the fallopian tubes and ovarian cells will lead to tumorigenic transformation of cells. The study by Appleby P etĀ al. found that the relative risk of cervical cancer in people who took Combined estrogenāprogestogen contraceptives (oral contraceptives or OCs) for ā„ 5 years was 1.9 times that of those who did not take it, and the incidence of cervical cancer was 10 years after ā„ withdrawal of the drug compared to that of those who did not take it (). The carcinogenicity of estrogen and ER to the uterine cervix has been most strongly demonstrated in HPV transgenic mice. It was found that these transgenic rats were more likely to progress to cervical cancer if they were given estrogen (ā). A large body of epidemiologic evidence suggests that endogenous and exogenous sex hormones, along with HPV infection, also affect a womanās risk of developing the disease (). In studies related to the development of cancer during menopause, age at menopause, as well as age at menarche, has been strongly associated with the risk of ovarian cancer in women. The increased risk of developing cervical cancer may be associated with ongoing estrogenic changes (, , ). Premature menopause is characterized by changes in various hormones in the female body, especially estrogen. When sustained changes in estrogen cause continuous beneficial or detrimental effects on the organism, it eventually leads to changes in the organism. Most importantly, some of the metabolic changes caused by estrogen have a significant impact on the development of cancer. There have been many studies on menopause, but they have not been adjusted or stratified for the potentially important variable of menopause (age). We have found that the incidence of gynecologic cancers varies by age at menopause, and that earlier menopause is associated with a higher risk of the gynecologic cancers ovarian and cervical cancer.
In our study, we found that age at menopause was negatively correlated with the incidence of ovarian and cervical cancer, and the earlier the age at menopause, the higher the prevalence, which may be related to the decrease in estrogen levels caused by menopause, and the earlier the menopause, the more fluctuating the changes in the bodyās hormone levels, which leads to a series of changes in lipid metabolism, mood, and cardiovascular changes, and the alteration of lipid metabolism may play an important role in the process of cancer development. Studies have shown that lower estrogen levels lead to an accumulation of central adipose tissue and that increased central obesity is associated with an increased risk of cardiometabolic diseases, certain cancers, osteoarthritis and dementia (, ). In addition, estrogen deficiency increases the risk of cardiovascular disease. Renin-angiotensin system activation and impaired arterial endothelial function. Altered lipid metabolism leads to impaired metabolism in adipose tissue and plays a key role in the synthesis of excess fatty acids, adipocytokines, pro-inflammatory cytokines, and reactive oxygen species, which cause lipid peroxidation and contribute to the development of insulin resistance, abdominal obesity, and dyslipidemia, which may be correlated with the prevalence of cancers caused by menopause (, ). Studies have shown that the use of hormone therapy has been shown to mitigate some, although not all, of these risks. Individualized hormone therapy is important for women with early estrogen deficiency, and premenopausal women may require higher doses to approach physiological concentrations. It is also important to address the psychological impact of early menopause and to assess fertility options and the need for contraception when ovaries are intact (ā). Age at menopause may influence the prevalence of ovarian and cervical cancer by affecting metabolism. Thus, we wanted to obtain information on the impact of age at menopause on future cardiovascular disease prevention, cancer screening, osteoporosis and fracture risk in women. In addition, it is important to realize the psychological impact of early menopause.
Conclusion
Our study can bring some inspiration for clinical work. For example, for female patients at different menopausal ages who should receive different health management, we can perform early screening and use various methods to reduce the negative effects of menopause. Like most studies, our study has some drawbacks. First, there may be differences in the organismal changes that result from different menopausal ages. Second, another issue to consider is whether postmenopausal women develop diseases of the reproductive oncology system related to their life circumstances. Our results do not establish a causal relationship between age at menopause and common reproductive system tumors, but only an association between their correlation obtained by analysis of the studyās observational data. Finally, we did not consider other potential confounders, such as sleep quality, socioeconomic status, etc. Further studies with more variables and larger populations should be conducted to validate our results.
Statements
Data availability statement
Publicly available datasets were analyzed in this study. This data can be found here: https://www.cdc.gov/nchs/nhanes/index.htm.
Author contributions
GC and MW conceived of and drafted the manuscript. HS, JL, and YF collected the data. HL, YS, and YZ managed and cleaned the data. BZ criticized and revised the manuscript. All authors contributed to the article and approved the submitted version.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by Contract 202112050617 of the Shandong Provincial Medical and Health Science and Technology Development Program.
Acknowledgments
The author thanks the staff and the participants of the NHANES study for their valuable contributions.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisherās note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
BrayFFerlayJSoerjomataramISiegelRLTorreLAJemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2018) 68(6):394ā424. doi: 10.3322/caac.21492
2
VuMYuJAwoludeOAChuangL. Cervical cancer worldwide. Curr Probl Cancer (2018) 42(5):457ā65. doi: 10.1016/j.currproblcancer.2018.06.003
3
PrenticeRLThomsonCACaanBHubbellFAAndersonGLBeresfordSAet al. Yasmeen S etĀ al: Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst (2007) 99(20):1534ā43. doi: 10.1093/jnci/djm159
4
WangMKartsonakiCGuoYLvJGanWChenZMet al. Factors related to age at natural menopause in China: results from the China Kadoorie Biobank. Menopause (2021) 28(10):1130ā42. doi: 10.1097/GME.0000000000001829
5
ChenLMKarlanBY. Early detection and risk reduction for familial gynecologic cancers. Clin Obstet Gynecol (1998) 41(1):200ā14. doi: 10.1097/00003081-199803000-00025
6
WalboomersJJacobsMVManosMMBoschFXMuƱozN. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 189(1):12ā9. doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
7
Endometrial cancer. Available at: https://www.ncbi.nlm.nih.gov/pubmed/16084259.
8
RozenbergSDi PietrantonioVVandrommeJGillesC. Menopausal hormone therapy and breast cancer risk. Best Pract Res Clin Endocrinol Metab (2021) 35(6):101577. doi: 10.1016/j.beem.2021.101577
9
TakahashiTAJohnsonKM. Menopause. Med Clin North Am (2015) 99(3):521ā34. doi: 10.1016/j.mcna.2015.01.006
10
TalaulikarV. Menopause transition: Physiology and symptoms. Best Pract Res Clin Obstet Gynaecol (2022) 81:3ā7. doi: 10.1016/j.bpobgyn.2022.03.003
11
SongSHWangDMoYYDingCShangP. [Antiosteoporotic effects of naringenin on ovariectomy-induced osteoporosis in rat]. Yao Xue Xue Bao (2015) 50(2):154ā61.
12
IorgaACunninghamCMMoazeniSRuffenachGUmarSEghbaliM. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biol Sex Differ (2017) 8(1):33. doi: 10.1186/s13293-017-0152-8
13
WuJDaiFLiCZouY. Gender differences in cardiac hypertrophy. J Cardiovasc Transl Res (2020) 13(1):73ā84. doi: 10.1007/s12265-019-09907-z
14
AmantFMoermanPNevenPTimmermanDVan LimbergenEVergoteI. Endometrial cancer. Lancet (2005) 366(9484):491ā505. doi: 10.1016/S0140-6736(05)67063-8
15
MandatoVDPalicelliATorricelliFMastrofilippoVLeoneCDicarloVet al. Should endometrial cancer treatment be centralized? Biol (Basel) (2022) 11(5):768. doi: 10.3390/biology11050768
16
TorokPKrasznaiZMolnarSLampeRJakabA. Preoperative assessment of endometrial cancer. Transl Cancer Res (2020) 9(12):7746ā58. doi: 10.21037/tcr-20-2068
17
PalmerMKTothPP. Trends in lipids, obesity, metabolic syndrome, and diabetes mellitus in the United States: an NHANES analysis (2003-2004 to 2013-2014). Obes (Silver Spring) (2019) 27(2):309ā14. doi: 10.1002/oby.22370
18
LiuZKuoPLHorvathSCrimminsEFerrucciLLevineM. A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study. PloS Med (2018) 15(12):e1002718. doi: 10.1371/journal.pmed.1002718
19
GhimireSBaralBKFengDSyFSRodriguezR. Is selenium intake associated with the presence of depressive symptoms among US adults? Findings from National Health and Nutrition Examination Survey (NHANES) 2011-2014. Nutrition (2019) 62:169ā76. doi: 10.1016/j.nut.2018.12.007
20
FainJA. Nhanes. Diabetes Educ (2017) 43(2):151. doi: 10.1177/0145721716686792
21
RattanPPenriceDDAhnJCFerrerAPatnaikMShahVHet al. Inverse association of telomere length with liver disease and mortality in the US population. Hepatol Commun (2022) 6(2):399ā410. doi: 10.1002/hep4.1803
22
ReesMAngioliRColemanRLGlasspoolRPlottiFSimonciniTet al. European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. Maturitas (2020) 134:56ā61. doi: 10.1016/j.maturitas.2020.01.005
23
MahboobifardFPourgholamiMHJorjaniMDargahiLAmiriMSadeghiSet al. Estrogen as a key regulator of energy homeostasis and metabolic health. BioMed Pharmacother (2022) 156:113808. doi: 10.1016/j.biopha.2022.113808
24
CarlettoBKogaAYNovatskiAMainardesRMLipinskiLCFaragoPV. Ursolic acid-loaded lipid-core nanocapsules reduce damage caused by estrogen deficiency in wound healing. Colloids Surf B Biointerfaces (2021) 203:111720. doi: 10.1016/j.colsurfb.2021.111720
25
PatelS. Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review. J Steroid Biochem Mol Biol (2017) 168:19ā25. doi: 10.1016/j.jsbmb.2017.01.009
26
DavisSRLambrinoudakiILumsdenMMishraGDPalLReesMet al. Menopause. Nat Rev Dis Primers (2015) 1:15004. doi: 10.1038/nrdp.2015.4
27
Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol (2015) 16(9):1061ā70. doi:Ā 10.1016/S1470-2045(15)00212-0
28
VincentAJLavenJS. Early menopause/premature ovarian insufficiency. Semin Reprod Med (2020) 38(4-05):235ā6. doi: 10.1055/s-0041-1722924
29
TorrealdaySPalL. Premature menopause. Endocrinol Metab Clin North Am (2015) 44(3):543ā57. doi: 10.1016/j.ecl.2015.05.004
30
EinsteinMHLevineNFNevadunskyNS. Menopause and cancers. Endocrinol Metab Clin North Am (2015) 44(3):603ā17. doi: 10.1016/j.ecl.2015.05.012
31
Alzheimer's Association. 2014 Alzheimer's disease facts and figures. Alzheimer's dementia (2014) 10(2):e47ā92. doi:Ā 10.1016/j.jalz.2014.02.001
32
GyamfiJKimJChoiJ. Cancer as a metabolic disorder. Int J Mol Sci (2022) 23(3):1155. doi: 10.3390/ijms23031155
33
ChenGGZengQTseGM. Estrogen and its receptors in cancer. Med Res Rev (2008) 28(6):954ā74. doi: 10.1002/med.20131
34
RiznerTL. Estrogen biosynthesis, phase I and phase II metabolism, and action in endometrial cancer. Mol Cell Endocrinol (2013) 381(1-2):124ā39. doi: 10.1016/j.mce.2013.07.026
35
Pena-GutierrezKMHernandez-OrtegaKBello-AlvarezCCamacho-ArroyoI. Expression and estrogen regulation of G protein-coupled estrogen receptor in human glioblastoma cells. Oncol Lett (2022) 24(5):397. doi:Ā 10.3892/ol.2022.13517
36
CunatSHoffmannPPujolP. Estrogens and epithelial ovarian cancer. Gynecol Oncol (2004) 94(1):25ā32. doi: 10.1016/j.ygyno.2004.03.026
37
International Collaboration of Epidemiological Studies of Cervical CApplebyPBeralVBerrington de GonzalezAColinDFranceschiSet al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet (2007) 370(9599):1609ā21. doi: 10.1016/S0140-6736(07)61684-5
38
RileyRRDuensingSBrakeTMungerKLambertPFArbeitJM. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res (2003) 63(16):4862ā71.
39
ShaiABrakeTSomozaCLambertPF. The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res (2007) 67(4):1626ā35. doi: 10.1158/0008-5472.CAN-06-3344
40
ArbeitJMHowleyPMHanahanD. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci U.S.A. (1996) 93(7):2930ā5. doi: 10.1073/pnas.93.7.2930
41
ChungSHFranceschiSLambertPF. Estrogen and ERalpha: culprits in cervical cancer? Trends Endocrinol metabolism: TEM (2010) 21(8):504ā11. doi: 10.1016/j.tem.2010.03.005
42
DunneramYGreenwoodDCCadeJE. Diet, menopause and the risk of ovarian, endometrial and breast cancer. Proc Nutr Soc (2019) 78(3):438ā48. doi: 10.1017/S0029665118002884
43
GongTTWangYLMaXX. Age at menarche and endometrial cancer risk: a dose-response meta-analysis of prospective studies. Sci Rep (2015) 5:14051. doi: 10.1038/srep14051
44
SternfeldBWangHQuesenberryCPJr.AbramsBEverson-RoseSAGreendaleGAet al. Physical activity and changes in weight and waist circumference in midlife women: findings from the Study of Women's Health Across the Nation. Am J Epidemiol (2004) 160(9):912ā22. doi: 10.1093/aje/kwh299
45
DavisSRCastelo-BrancoCChedrauiPLumsdenMANappiREShahDet al. Understanding weight gain at menopause. Cli- macteric (2012) 15(5):419ā29. doi: 10.3109/13697137.2012.707385
46
BianXLiuRMengYXingDXuDLuZ. Lipid metabolism and cancer. J Exp Med (2021) 218(1):e20201606. doi: 10.1084/jem.20201606
47
KoSHKimHS. Menopause-associated lipid metabolic disorders and foods beneficial for postmenopausal women. Nutrients (2020) 12(1):202. doi: 10.3390/nu12010202
48
FaubionSSKuhleCLShusterLTRoccaWA. Long-term health consequences of premature or early menopause and considerations for management. Climacteric (2015) 18(4):483ā91. doi: 10.3109/13697137.2015.1020484
49
PaciucJ. Hormone therapy in menopause. Adv Exp Med Biol (2020) 1242:89ā120. doi: 10.1007/978-3-030-38474-6_6
50
ShusterLTRhodesDJGostoutBSGrossardtBRRoccaWA. Premature menopause or early menopause: long-term health consequences. Maturitas (2010) 65(2):161ā6. doi: 10.1016/j.maturitas.2009.08.003
Summary
Keywords
retrospective study, menopause, cancer, gynecology, NHANES
Citation
Cheng G, Wang M, Sun H, Lai J, Feng Y, Liu H, Shang Y, Zhao Y, Zuo B and Lu Y (2023) Age at menopause is inversely related to the prevalence of common gynecologic cancers: a study based on NHANES. Front. Endocrinol. 14:1218045. doi: 10.3389/fendo.2023.1218045
Received
06 May 2023
Accepted
31 October 2023
Published
16 November 2023
Volume
14 - 2023
Edited by
Karen Elizabeth Nava-Castro, National Autonomous University of Mexico, Mexico
Reviewed by
Roberto Altamirano, University of Chile, Chile; Sajith Kumar S., National Institute of Epidemiology (ICMR), India
Updates
Copyright
Ā© 2023 Cheng, Wang, Sun, Lai, Feng, Liu, Shang, Zhao, Zuo and Lu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Bingli Zuo, binglizuo@126.com; Youhua Lu, luyouhua@126.com
ā These authors have contributed equally to this work and share first authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.